Sclerostin in Institutionalized Elderly Women: Associations with Quantitative Bone Ultrasound, Bone Turnover, Fractures, and Mortality

To evaluate the association between levels of circulating sclerostin (an emerging biomarker and important regulator of bone formation) and laboratory parameters of bone and mineral metabolism, bone mineral density and quality measured using quantitative ultrasound (QUS), fracture risk, and mortality.

[1]  C. Becker.  Sclerostin inhibition for osteoporosis--a new approach. , 2014, The New England journal of medicine.

[2]  Cesar Libanati,et al.  Romosozumab in postmenopausal women with low bone mineral density , 2014, The New England journal of medicine.

[3]  P. D’Haese,et al.  Sclerostin: Another vascular calcification inhibitor? , 2013, The Journal of clinical endocrinology and metabolism.

[4]  R. Chapurlat,et al.  Lower fracture risk in older men with higher sclerostin concentration: A prospective analysis from the MINOS study , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  I. Kalajzic,et al.  Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  O. Babatunde,et al.  Quantitative Ultrasound and bone's response to exercise: a meta analysis. , 2013, Bone.

[7]  R. Obeid,et al.  One year B and D vitamins supplementation improves metabolic bone markers , 2013, Clinical chemistry and laboratory medicine.

[8]  R. Chapurlat,et al.  Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study , 2013, Osteoporosis International.

[9]  S. Mousa,et al.  High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: The center of excellence for osteoporosis research study , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  A. Rouzi,et al.  Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. , 2012, The Journal of clinical endocrinology and metabolism.

[11]  M. Bouxsein,et al.  Serum sclerostin increases in healthy adult men during bed rest. , 2012, Journal of Clinical Endocrinology and Metabolism.

[12]  G. Loots,et al.  Absence of sclerostin adversely affects B‐cell survival , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  S. Cummings,et al.  Serum sclerostin and risk of hip fracture in older Caucasian women. , 2012, The Journal of clinical endocrinology and metabolism.

[14]  G. Lipowsky,et al.  Ultrasound for the assessment of bone quality in preterm and term infants , 2012, Journal of Perinatology.

[15]  S. Vasikaran,et al.  Current Recommendations for Laboratory Testing and Use of Bone Turnover Markers in Management of Osteoporosis , 2012, Annals of laboratory medicine.

[16]  T. Pieber,et al.  Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. , 2012, The Journal of clinical endocrinology and metabolism.

[17]  A. Rouzi,et al.  Determinants of serum sclerostin in healthy pre‐ and postmenopausal women , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  L. E. Lanyon,et al.  Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered , 2011, Osteoporosis International.

[19]  L. Lanyon,et al.  Role of Endocrine and Paracrine Factors in the Adaptation of Bone to Mechanical Loading , 2011, Current osteoporosis reports.

[20]  S. Papapoulos.  Targeting sclerostin as potential treatment of osteoporosis , 2011, Annals of the rheumatic diseases.

[21]  L. Melton,et al.  Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  P. Kostenuik,et al.  Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. , 2010, The Journal of clinical endocrinology and metabolism.

[23]  S. Silverman.  Sclerostin , 2010, Journal of osteoporosis.

[24]  C. Löwik,et al.  Sclerostin: Current Knowledge and Future Perspectives , 2010, Calcified Tissue International.

[25]  Gerhard Hawa,et al.  Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. , 2010, The Journal of clinical endocrinology and metabolism.

[26]  P. Gerdhem,et al.  Bone turnover markers and prediction of fracture: A prospective follow‐up study of 1040 elderly women for a mean of 9 years , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  Guoyin Feng,et al.  Sclerostin Mediates Bone Response to Mechanical Unloading Through Antagonizing Wnt/β‐Catenin Signaling , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  Matthew R Allen,et al.  Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin* , 2008, Journal of Biological Chemistry.

[29]  R. Baron,et al.  Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. , 2007, Endocrinology.

[30]  G. Riedmüller,et al.  Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements. , 2007, The Journal of clinical endocrinology and metabolism.

[31]  A. Tiran,et al.  Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. , 2006, The Journal of clinical endocrinology and metabolism.

[32]  C-C Glüer,et al.  [Quantitative ultrasound]. , 2006, Der Radiologe.

[33]  H. Valkenburg,et al.  The incidence of hip fractures in independent and institutionalized elderly people , 2006, Osteoporosis International.

[34]  Peng Liu,et al.  Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling* , 2005, Journal of Biological Chemistry.

[35]  I. Reid,et al.  Residential status and risk of hip fracture. , 1999, Age and ageing.

[36]  T Lee-Joe,et al.  The risks of hip fracture in older people from private homes and institutions. , 1996, Age and ageing.